Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Daiichi Sankyo Co : Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/24/2012 | 07:59am CET

For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, General Manager, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan Tokyo, Japan (March 23, 2012) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will develop hydromorphone hydrochloride, a narcotic analgesic that has yet to be approved in Japan.

Hydromorphone hydrochloride is an opiate, narcotic analgesic that has been available outside of Japan for over 80 years. Although it is the standard for pain management for cancer pain treatment according to WHO guidelines, hydromorphone hydrochloride has yet to be approved in Japan.
Mundipharma K.K. had been requested by the Study Group on Unapproved and Off-label Drugs of High Medical Need* to develop hydromorphone hydrochloride in Japan, but after subsequent discussions it was decided that Daiichi Sankyo would develop the drug instead. The development of hydromorphone hydrochloride will contribute to the improvement of pain management options in Japan, and Daiichi Sankyo, through its commitment to corporate social responsibility, will continue to work to make unapproved and off-label drugs available in Japan in order to further contribute to medical treatment options for patients.
*A study group set up by Japan's Ministry of Health, Labour and Welfare to promote development by pharmaceutical companies of unapproved and off-label drugs in Japan that have been approved in the United States and Europe.
###

distributed by

This press release was issued by Daiichi Sankyo Co. Ltd. and was initially posted at http://www.daiichisankyo.com/news/20120321_376_E2.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-24 07:53:56 AM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
12/15 VERNALIS : enters into research collaboration with Daiichi Sankyo
12/15 DAIICHI SANKYO : Once-Daily, Oral LIXIANA Met Primary Endpoint in Investigationa..
12/15 PUMA BIOTECHNOLOGY : Daiichi Sankyo and Puma Biotechnology Announce Research Col..
12/14 DAIICHI SANKYO : Findings on Guanylate Cyclase Discussed by Investigators at Dai..
12/14 DAIICHI SANKYO : Presents Updated Data for DS-8201 in Patients with HER2-Express..
12/14 DAIICHI SANKYO : Vernalis, Daiichi Sankyo work together on new cancer targets
12/14 Daiichi ditches Nektar following cancer drug flop
12/14 DAIICHI SANKYO : Vernalis, Daiichi form oncology drug discovery collaboration
12/11 DAIICHI SANKYO : Subsidiary Daiichi Sankyo Espha to Launch New Generic Drugs
12/07 REPORTS OUTLINE MEDICINAL CHEMISTRY : ...
More news
News from SeekingAlpha
12/14 Daiichi Sankyo (DSNKY) Investor Presentation - Slideshow
12/12 Daiichi Sankyo and Puma Biotech team up with Sloan Kettering to investigate c..
12/07 Daiichi's novel antibody-drug conjugate DS-8201 shows treatment effect in ear..
12/01 Daiichi Sankyo bails on blood clot dissolving agent
11/12 Daiichi Sankyo Co., Ltd. ADR 2018 Q2 - Results - Earnings Call Slides
Financials ( JPY)
Sales 2018 932 B
EBIT 2018 -
Net income 2018 56 920 M
Finance 2018 308 B
Yield 2018 2,46%
P/E ratio 2018 32,23
P/E ratio 2019 30,66
EV / Sales 2018 1,84x
EV / Sales 2019 1,90x
Capitalization 2 021 B
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Technical analysis trends DAIICHI SANKYO COMPANY, LI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 2 769  JPY
Spread / Average Target -2,8%
EPS Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura IR Contact, Manager-Finance & Accounting
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED18.41%17 940
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386